Legend Biotech
LEGN
150 hedge funds and large institutions have $2.9B invested in Legend Biotech in 2022 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 50 increasing their positions, 50 reducing their positions, and 22 closing their positions.
208% more call options, than puts
Call options by funds: $47.7M | Put options by funds: $15.5M
56% more capital invested
Capital invested by funds: $1.86B → $2.9B (+$1.04B)
45% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 22
40% more funds holding in top 10
Funds holding in top 10: 5 → 7 (+2)
6% more funds holding
Funds holding: 141 → 150 (+9)
0.39% more ownership
Funds ownership: 16.7% → 17.09% (+0.39%)
0% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 50
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$179M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$32M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$24M |
| 4 |
ITP
Iron Triangle Partners
Cos Cob,
Connecticut
|
+$20.9M |
| 5 |
SC
Samlyn Capital
New York
|
+$19.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$106M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$48.7M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
-$25.9M |
| 4 |
PA
Perceptive Advisors
New York
|
-$22.4M |
| 5 |
CII
Capital International Inc
Los Angeles,
California
|
-$22.2M |
LEGN Hedge Fund Activity: Q2 2022 in Review
150 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Legend Biotech (LEGN) for Q2 2022, worth a combined $2.9B — up 56% from $1.86B a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new LEGN positions and 22 closed out — a net gain of 10 holders — while 50 added to existing stakes and 50 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $179M. The largest seller was HHLR Advisors, cutting an estimated $106M.
- 150 institutional investors held Legend Biotech (LEGN) as of Q2 2022, up from 141 in Q1 2022.
- Funds reported $2.9B of Legend Biotech stock for Q2 2022, up 56% quarter-over-quarter.
- 32 funds opened new Legend Biotech positions in Q2 2022 and 22 closed out, a net change of +10 holders.
- The largest Legend Biotech buyer in Q2 2022 was Fidelity Investments, an estimated $179M added.
- The largest Legend Biotech seller in Q2 2022 was HHLR Advisors, an estimated $106M sold.
Based on aggregated 13F filings for Q2 2022.